Chronic hepatitis D at a standstill: Where do we go from here?

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 1, 2014, Pages 68-71

  Ciancio, Alessia ^a   Rizzetto, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CYTOKINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; VIRUS RNA;

CHRONIC DRUG ADMINISTRATION; DELTA AGENT HEPATITIS; DRUG TOLERABILITY; EPIDEMIC; EUROPE; HEALTH PROMOTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS DELTA VIRUS; HUMAN; INCIDENCE; INFECTION RISK; LIFE CYCLE; MAURITANIA; MONGOLIA; NONHUMAN; PAKISTAN; PREVALENCE; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PROTEIN PRENYLATION; PROTEIN PROCESSING; PUBLIC HEALTH PROBLEM; REVIEW; RNA INTERFERENCE; TREATMENT RESPONSE; UNITED STATES; VIRAL CLEARANCE; VIRION; VIRUS CARRIER; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; ENDPOINT DETERMINATION; HEPATITIS B SURFACE ANTIGENS; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84891743844     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.164     Document Type: Review

References (45)

1. Rizzetto, M. Hepatitis D: thirty years after. J. Hepatol. 50, 1043-1050 (2009)
2. Taylor, J. M. Structure and replication of hepatitis delta virus RNA. Curr. Top. Microbiol. Immunol. 307, 1-23 (2006)
3. World Health Organization. Weekly epidemiological report. Hepatitis B position. 84, 405-420 (2009)
4. Rizzetto, M., Ponzetto, A. & Forzani, I. Epidemiology of hepatitis delta virus: overview. Prog. Clin. Biol. Res. 364, 1-20 (1991)
5. Rizzetto, M. & Ciancio, A. Epidemiology of hepatitis D. Semin. Liver Dis. 32, 211-219 (2012)
6. Huo, T. I. et al. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J. Gastroenterol. Hepatol. 12, 747-751 (1997)
7. Kao, J. H., Chen, P. J., Lai, M. Y. & Chen, D. S. Hepatitis D virus genotypes in intravenous drug users in Taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. J. Clin. Microbiol. 40, 3047-3049 (2002)
8. Gaeta, G. B. et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology 46, 1312-1313 (2007)
9. Stroffolini, T. et al. Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. J. Med. Virol. 81, 1999-2006 (2009)
10. Heidrich, B. et al. Virological and clinical characteristics of delta hepatitis in Central Europe. J. Viral Hepat. 16, 883-894 (2009)
11. Cross, T. J. et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J. Med. Virol. 80, 277-282 (2008)
12. Le Gal, F. et al. Hepatitis D virus infection. Not a vanishing disease in Europe. Hepatology 45, 1332-1333 (2007)
13. Erhardt, A. et al. Socioepidemiological data on hepatitis delta in a German university clinic-increase in patients from Eastern Europe and the former Soviet Union. Z. Gastroenterol. 41, 523-526 (2003)
14. Bialek, S. R., Bower, W. A. & Mottram, K. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J. Urban Health 82, 468-478 (2005)
15. Kucirka, L. M. et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J. Infect. Dis. 202, 845-852 (2010)
16. Gish, R. G. et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J. Gastroenterol. Hepatol. http://dx.doi.org/10.1111/jgh.12217.
17. Holmberg, S. D. & Ward, J. W. Hepatitis delta: seek and ye shall find. J. Infect. Dis. 202, 822-824 (2010)
18. Niro, G. A., Rosina, F. & Rizzetto, M. Treatment of hepatitis D. J. Viral Hepat. 12, 2-9 (2005)
19. Farci, P. et al. Treatment of chronic hepatitis D with interferon ?-2a. N. Engl. J. Med. 330, 88-94 (1994)
20. Ciancio, A. & Rizzetto, M. PEG-IFN for the treatment of hepatitis D. Nat. Rev. Gastroenterol. Hepatol. 8, 304-306 (2011)
21. Castelnau, C. et al. Efficacy of peginterferon ?-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 44, 728-735 (2006)
22. Niro, G. A. et al. Pegylated interferon ?-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 44, 713-720 (2006)
23. Erhardt, A. et al. Treatment of chronic hepatitis delta with pegylated interferon-?2b. Liver Int. 26, 805-810 (2006)
24. Wedemeyer, H. et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N. Engl. J. Med. 364, 322-331 (2011)
25. Heidrich, B. et al. Long-Term follow-up after peg-ifna2a based therapy of chronic hepatitis delta [abstract]. J. Hepatol. 58 (Suppl. 1), S20 (2013)
26. Niro, G. A. et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment. Pharmacol. Ther. 22, 227-232 (2005)
27. Yurdaydin, C. et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J. Viral Hepat. 15, 314-321 (2008)
28. Kabaam, G. et al. Entecavir treatment of chronic hepatitis D. Clin. Infect. Dis. 55, 645-650 (2012)
29. Kao, J. H. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev. Gastroenterol. Hepatol. 2, 553-562 (2008)
30. Lai, M. M. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J. Virol. 79, 7951-7958 (2005)
31. Singh, S. et al. Design of potential siRNA molecules for hepatitis delta virus gene silencing. Bioinformation 8, 749-757 (2012)
32. Chang, J. & Taylor, J. M. Susceptibility of human hepatitis delta virus RNAs to small interfering RNA action. J. Virol. 77, 9728-9731 (2003)
33. Sureau, C. The role of the HBV envelope proteins in the HDV replication cycle. Curr. Top. Microbiol. Immunol. 307, 113-131 (2006)
34. Abou-Jaoud, G. & Sureau, C. Entry of hepatitis delta virus requires the conserved cysteine residues of the hepatitis B virus envelope protein antigenic loop and is blocked by inhibitors of thiol-disulfide exchange. J. Virol. 81, 13057-13066 (2007)
35. Ltgehetmann, M. et al. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55, 685-694 (2012)
36. Komla-Soukha, I. & Sureau, C. A tryptophan-rich motif in the carboxyl terminus of the small envelope protein of hepatitis B virus is central to the assembly of hepatitis delta virus particles. J. Virol. 80, 4648-4655 (2006)
37. Vietheer, P. T., Netter, H. J., Sozzi, T. & Bartholomeusz, A. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J. Virol. 79, 6570-6573 (2005)
38. Andreone, P., Spertini, F. & Negro, F. Lamivudine-Associated remission of chronic hepatitis delta. Ann. Intern. Med. 132, 598 (2000)
39. Shih, H. H. et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J. Virol. 82, 2250-2264 (2008)
40. Huang, W. H., Chen, C. W., Wu, H. L. & Chen, P. J. Post-Translational modification of delta antigen of hepatitis D virus. Curr. Top. Microbiol. Immunol. 307, 91-112 (2006)
41. Glenn, J. S. Prenylation of HDAg and antiviral drug development. Curr. Top. Microbiol. Immunol. 307, 133-149 (2006)
42. Bordier, B. B. et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J. Virol. 76, 10465-10472 (2002)
43. Bordier, B. B. et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J. Clin. Invest. 112, 407-414 (2003)
44. Ouzan, D., Pnaranda, G., Joly, H. & Halfon, P. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic delta. J. Hepatol. 58, 1258-1259 (2013)
45. Muir, A. J. et al. Peginterferon ?-1a (?) compared with peginterferon ?-2a (?) in treatment-naive patients with HCV genotypes 1 or 4: SVR24 results from EMERGE phase 2b [abstract]. J. Hepatology 56, 299A (2012)